美股市场个股详情

NKTR 内克塔治疗

添加自选

1.6500
+0.0800+5.10%

收盘价 05/06 16:00 (美东)

1.6300
-0.0200-1.21%

盘后 18:33 (美东)

3.03亿总市值-1137市盈率TTM

内克塔治疗股票讨论区

登录发表评论

Trytosaveabit

04/18 05:12

Update

$内克塔治疗(NKTR.US)$ Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq

Trytosaveabit

03/05 17:45

A Bio research company with these financials but trading this low! How sad

$内克塔治疗(NKTR.US)$ • Nektar Therapeutics has regained full rights to its drug candidate REZPEG and is advancing Phase 2b studies for atopic dermatitis and alopecia areata.
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...

Nektar Therapeutics' CEO, Howard Robin, is pleased with the deal, stating it strengthens the company's finances and extends its cash runway to Q3 2026. He also emphasized the potential of rezpegaldesleukin, a novel biologic in Phase 2b studies.

Press Release: Nektar Therapeutics Announces $30 Million Private Placement Financing With TCGX

Trytosaveabit

2023/12/12 19:41

Update

$内克塔治疗(NKTR.US)$ Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255
MT Newswires· 1 min ago
Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells.
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...

Lucky2828

2023/11/16 07:38

$内克塔治疗(NKTR.US)$ It needs some suberb news that can drive the stock price. It's not for short-term investment.

Nektar Therapeutics(NKTR) Post-Mkt Price 0.5639 +0.70%

Trytosaveabit

2023/10/13 20:38

News!

$内克塔治疗(NKTR.US)$ Nektar Presents New Responder Data For Rezpegaldesleukin, A First-In-Class Selective Regulatory T-cell Therapy, In Late-Breaking News Oral Presentation At 2023 EADV Congress
Benzinga· 1 min ago
– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period –
– New Data Presented Show Encouraging Proportion of Patient-Reported Responder Outcomes for DLQ...

HutchingsNyamom

2023/09/16 05:35

$内克塔治疗(NKTR.US)$ is up 21% for the week and today announced positive results from their clinicals .. trading volume has been up for 4 days

暂无评论

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议

美股

综合热度